Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2005
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways for tissue repair and regeneration. The company operates in a single segment (developmental biology products) and relies heavily on strategic collaborations with major pharmaceutical companies (Genentech, Wyeth, Procter & Gamble, Ortho Biotech) for funding and commercialization. Its lead product candidate, a topical therapy for basal cell carcinoma, is in Phase I clinical trials and is co-developed with Genentech.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2005 | Nine Months Ended Sep 30, 2005 | Balance Sheet (Sep 30, 2005) |
|---|---|---|---|
| Net Revenues | $1,815,142 | $2,803,052 | N/A |
| Gross Revenues | $2,634,633 | $8,501,045 | N/A |
| Contra-Revenues (Genentech Co-dev) | ($819,491) | ($5,697,993) | N/A |
| Net Loss | ($3,630,713) | ($13,418,616) | N/A |
| Loss Per Share (Basic/Diluted) | ($0.08) | ($0.28) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $22,884,331 |
| Marketable Securities | N/A | N/A | $20,013,996 |
| Total Current Assets | N/A | N/A | $45,993,289 |
| Total Current Liabilities | N/A | N/A | $9,936,510 |
| Long-Term Debt | N/A | N/A | $1,187,500 |
| Accumulated Deficit | N/A | N/A | ($676,391,326) |
Liquidity: As of September 30, 2005, the company held approximately $42.9 million in cash, cash equivalents, and marketable securities. Management estimates these resources, combined with expected collaboration payments, will fund operations into the second half of 2007.
Material Changes vs. Prior Period
- Revenue Composition: Gross revenues increased 77% in the third quarter and 146% in the nine-month period compared to the prior year, driven primarily by increased research and development contract revenue from Genentech. However, Net Revenues decreased 19% for the nine-month period due to significant contra-revenue charges.
- Contra-Revenues: The company recorded $820,000 (Q3) and $5.7 million (9-month) in contra-revenues. These represent the company's equal share of U.S. development costs for the basal cell carcinoma program co-developed with Genentech, recorded as a reduction of revenue under EITF 01-9.
- Accounting Corrections: The company corrected errors in prior periods regarding the valuation of shares issued to Genentech and Wyeth. This resulted in a cumulative revenue reduction of $460,000 in the third quarter of 2005 and an increase in additional paid-in capital of $1.6 million.
- Operating Expenses: Research and Development (R&D) expenses increased 16% in Q3 and 13% in the nine-month period, largely due to increased spending on discovery research programs (including the Spinal Muscular Atrophy Foundation grant). General and Administrative (G&A) expenses decreased 14% in Q3 and 5% in the nine-month period, despite a $500,000 charge for expected loss of subtenant income.
- Debt Structure: The company converted a convertible note payable to Elan Pharma International into common stock in January 2005. New debt obligations were incurred for equipment financing with Boston Private Bank & Trust Company.
Guidance, Outlook, and Risks
- Outlook: Curis does not expect to achieve profitability in the foreseeable future. The company anticipates incurring significant operating losses as it advances product candidates. It expects to fund operations through existing cash, collaboration payments, and potential future financing.
- Co-Development Costs: The company expects to incur approximately $20 million in development expenses through Phase II clinical trials for the basal cell carcinoma candidate, with Phase II completion anticipated in mid-2007.
- Accounting Risks: The company disclosed recent accounting errors related to revenue recognition and equity valuation. While management deemed these immaterial, they noted that if the SEC Staff disagrees, the company may be required to restate prior financial statements, which could impact stock price and invite litigation.
- Collaboration Risks: The company is highly dependent on collaborators (Genentech, Wyeth, P&G) for revenue and product development. Termination of these agreements or failure to achieve milestones would materially harm operations.
- Lease Contingency: A subtenant at the company's Cambridge facility indicated potential default. The company recorded a $500,000 charge for the expected loss of sublease income over the remaining lease term (through April 2007).
- Stock-Based Compensation: The company plans to adopt SFAS No. 123(R) in the first quarter of fiscal 2006, which will materially impact reported results of operations by requiring fair value expensing of stock options.
Investor Verification Checklist
- Accounting Restatement Risk: Verify the SEC Staff's final determination regarding the materiality of the revenue and equity valuation errors disclosed in Q3 2005.
- Genentech Co-Development Terms: Confirm the specific cost-sharing mechanics and the impact of the $20 million projected Phase II spend on future cash burn rates.
- Sublease Default Status: Monitor the status of the subtenant at 61 Moulton Street to assess if the $500,000 liability estimate requires adjustment or if additional cash outflows are needed.
- Cash Runway: Validate the assumption that collaboration payments will continue as planned to support operations through mid-2007 without additional dilutive financing.
- Phase I Trial Progress: Track the enrollment and safety data of the basal cell carcinoma Phase I trial, as failure here would jeopardize the primary revenue driver and co-development partnership.